



# ACADEMY OF SCIENCES OF THE CZECH REPUBLIC

Based upon Act No. 283/1992 Coll., on the Academy of Sciences of the Czech Republic, as subsequently amended, and upon Act No. 341/2005 Coll., on public research institutions, and in accordance with the Statutes of the Academy of Sciences of the Czech Republic issued on 24 May 2006, the Academy of Sciences of the Czech Republic (hereinafter ASCR) hereby issues

## **the Foundation Deed of the Institute of Experimental Medicine of the ASCR, v. v. i.**

### I.

(1) The Institute was established by a resolution of the sixty-fourth session of the Presidium of the Czechoslovak Academy of Sciences (hereinafter CSAS) held on 29 May 1974, which took effect on 1 January 1975, under the name the Institute of Experimental Medicine of the CSAS. Under section 18 (2) of Act No. 283/1992 Coll., the Institute became an entity of the ASCR as of 31 December 1992. By a resolution of the nineteenth session of the Academy Assembly of the ASCR held on 12 December 2001, the Institute of Pharmacology of the ASCR, identification number 67985947, located in Prague 4, Vídeňská 1083, was consolidated into the Institute of Experimental Medicine of the ASCR, effective from 1 January 2002.

(2) Under Act No. 341/2005 Coll., the legal status of the Institute of Experimental Medicine of the ASCR will be transformed from a state contributory organisation into a public research institution (abbreviated as v. v. i.) from 1 January 2007.

### II.

(1) The Institute of Experimental Medicine of the ASCR, v. v. i., (hereinafter IEM) is established for an indefinite period as a legal entity with identification number 68378041, and is located in Prague 4, Vídeňská 1083, Postal Code 142 20.

(2) The founder of the IEM is the ASCR, an organisational body of the state, identification number 60165171, headquartered in Prague 1, Národní 1009/3, Postal Code 117 20.

### III.

(1) The purpose for which the IEM has been established is to carry out scientific research in the field of biomedicine, to contribute to the utilisation of its research results, and to provide a research infrastructure.

(2) The principal activity of the IEM is scientific research in biomedicine, especially in the fields of cell biology and pathology, genotoxicology, teratology, biochemistry, neurosciences, stem cells, tissue repair, nanomedicine, and the development and verification of analytical, diagnostic and therapeutic methods based on the results of fundamental research. The IEM also conducts research in the field of pharmacology, particularly immunopharmacology and neuropsychopharmacology. The IEM contributes to raising the level of knowledge and education, the innovation of therapeutic drugs and



medicaments and to utilising the results of scientific research in practice. It acquires, processes and disseminates scientific information and issues scientific and specialised publications (monographs, journals, proceedings, etc.). It provides scientific assessments, professional opinions and recommendations, consulting and advisory services. In cooperation with universities, the IEM carries out doctoral study programmes and provides training for young scientists. Within the scope of its activity, the IEM promotes international cooperation, including the organisation of joint research projects with foreign partners, participation in exchange programmes for scientists and the exchange of scientific information, as well as the preparation of joint publications. The IEM organises scientific meetings, conferences and seminars at the national and international levels and provides the infrastructure for research including the experimental animal breeding. It pursues its aims both independently and in cooperation with universities, especially with faculties of medicine, departmental institutes of the Ministry of Health of the Czech Republic and with other research and professional institutions.

(3) The other activity of the IEM includes the production and sale of nanofibres and nanoparticles, hydrogels and artificial carriers of cells, stem cells and preparations containing stem cells, cartilaginous implants, specific cultivation media and supportive therapeutic preparations. The total extent of the other activity may not exceed 10 percent of the working capacity of the IEM. The conditions of the other activity are determined by the respective entrepreneurial authorisations and the Act on Public Research Institutions.

#### IV.

(1) The director, the Board and the Supervisory Board are the bodies of the IEM. The director is the statutory body of the IEM and is entitled to act on behalf of the IEM.

(2) Basic organisational units of the IEM are scientific departments responsible for research and development, and service departments responsible for provision of the infrastructure.

(3) The detailed organisational structure of the IEM is regulated by rules of organisation issued by the director after being approved by the Board.

#### V.

The foundation deed will become effective on 1 January 2007 and will supersede the foundation deed of the Institute of Experimental Medicine of the ASCR dated 1 September 1993, as subsequently amended by a modification dated 25 May 1998, Addendum No. 1 dated 31 December 2001 and Addendum No. 2 dated 29 August 2005 (the full text having been issued on 29 August 2005).

Prague, 20 December 2006  
Ref. No.: K-555/P/06

Prof. Václav Pačes  
President of the ASCR